753924-48-0Relevant academic research and scientific papers
FORMAMIDE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
-
Paragraph 0138-0139, (2021/05/14)
The present invention relates to a formamide compound, a preparation method therefor and an application thereof. The structure of the compound is shown in formula (I), and the definition of each variable in the formula is as provided in the description. The compound is capable of inhibiting the activity of ASK1 kinase. The compound of the present invention may be used in the treatment/prevention of diseases associated with ASK1 kinase, such as inflammatory diseases, metabolic diseases, autoimmune diseases, cardiovascular diseases, neurodegenerative diseases, cancers and other diseases.
Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective NaV1.7 Inhibitors for the Treatment of Pain
Luo, Guanglin,Chen, Ling,Easton, Amy,Newton, Amy,Bourin, Clotilde,Shields, Eric,Mosure, Kathy,Soars, Matthew G.,Knox, Ronald J.,Matchett, Michele,Pieschl, Rick L.,Post-Munson, Debra J.,Wang, Shuya,Herrington, James,Graef, John,Newberry, Kimberly,Sivarao, Digavalli V.,Senapati, Arun,Bristow, Linda J.,Meanwell, Nicholas A.,Thompson, Lorin A.,Dzierba, Carolyn
, p. 831 - 856 (2019/01/21)
3-Aryl-indole and 3-aryl-indazole derivatives were identified as potent and selective Nav1.7 inhibitors. Compound 29 was shown to be efficacious in the mouse formalin assay and also reduced complete Freund's adjuvant (CFA)-induced thermal hyper
ERBB/BTK INHIBITORS
-
, (2019/08/26)
Disclosed are compounds inhibiting ErbBs (e. g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compou
HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2
-
, (2018/03/25)
The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these
PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2
-
, (2018/05/03)
The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these
ACYL SULFONAMIDE NaV1.7 INHIBITORS
-
, (2017/11/15)
The present disclosure relates to compounds of formula I which inhibit NaV1.7, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT
-
, (2014/05/24)
The present invention relates to a novel compound having GPR40 receptor agonist activity that promotes insulin secretion and inhibits blood sugar rise after glucose loading, and is thereby useful for the treatment of diabetes and complications thereof, the preparation method thereof and pharmaceutical composition containing them as an active ingredient.
P38 inhibitors and methods of use thereof
-
Page/Page column 31; sheet 33, (2008/06/13)
This invention relates to inhibitors of p38, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders mediated by p38.
